What Changed on February 27, 2026
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience that BPC-157, along with approximately 13 other previously restricted peptides, would move from the FDA’s Category 2 list back to Category 1. This is one of the most significant regulatory changes in the peptide space in years.
Category 2 status, imposed in September 2023, had effectively banned licensed 503A compounding pharmacies from preparing BPC-157. Physicians could no longer write prescriptions for it through regulated channels. The result was a surge in grey-market sourcing — patients buying from unregulated online vendors with no physician oversight and no quality verification.
Category 1 status reverses that. Licensed 503A compounding pharmacies can now legally prepare BPC-157 again. But only with a valid physician prescription for a specific patient. This is not over-the-counter access. It is regulated, physician-supervised access — which is precisely how it should work.
What Category 1 Actually Means
The FDA’s bulk drug substance list for 503A compounding pharmacies divides compounds into categories based on their clinical need, safety profile, and whether they present a risk to public health. Category 1 substances can be compounded by licensed pharmacies for individual patients when prescribed by a licensed physician.
This does not mean BPC-157 is FDA-approved as a finished drug product. It is not. It means the FDA has determined that BPC-157 has sufficient clinical need and acceptable safety profile to be legally compounded on a patient-specific basis. Every vial must still be made to order for a specific patient under a specific prescription.
What Patients Need to Do
If you are interested in BPC-157 therapy, the path is now clear and legal:
- Consult with a licensed physician who specializes in peptide therapy or functional medicine
- Receive a clinical evaluation and, if appropriate, a prescription
- Have that prescription filled by a licensed 503A compounding pharmacy
- Receive your medication with a full Certificate of Analysis confirming purity and identity
What you should not do: purchase BPC-157 from unregulated online vendors, even those claiming “research use only” status. The regulatory landscape has changed. Regulated access now exists. Use it.
Which Other Peptides Were Reclassified
The February 2026 announcement covered approximately 14 peptides moving from Category 2 to Category 1. This includes TB-500, CJC-1295, Ipamorelin, Thymosin Alpha-1, and several others. The formal FDA publication is expected in Q2-Q3 2026, at which point compounding pharmacies will have full regulatory clarity.
My Body Labs and the Reclassification
My Body Labs was built in anticipation of exactly this regulatory shift. Our physician network, pharmacy partnerships, and intake platform are designed to make regulated peptide access as simple and fast as possible. If you’re interested in BPC-157 therapy, join our waitlist to be first in line when we open patient enrollment.